智通财经APP获悉，建银国际发布研报称，上调康方生物(09926)目标价6%，由85港元升至90港元，维持“跑赢大市”评级。该行上调康方生物2026年经调整盈测3%至12亿元人民币，并预期AK112或在2025年年底前提交美国FDA市场审批，且有可能在2026年底前获批。
报告表示，由于康方生物较低的营运支出与销售额比率，集团2024年及其下半年业绩超预期。该行表示，在微调毛利率和开支销售比预测后，该行现预计康方生物国际财务报告准则及经调整2025年末首次实现净利，分别为2300万元/1.03亿元人民币。
更多港股重磅资讯，下载智通财经app
更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.